Macquarie Group’s Xenon Pharmaceuticals XENE Stock Holding History

Macquarie Group’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-132	Closed	-$24K	–	2155
2022 Q3	$24K	Sell	132 -539	-80%	-$19.4K	﹤0.01%	2153
2022 Q2	$20K	Hold	671	–	–	﹤0.01%	2315
2022 Q1	$21	Sell	671 -2,843	-81%	-$85.1K	﹤0.01%	2380
2021 Q4	$110K	Hold	3,514	–	–	﹤0.01%	1911
2021 Q3	$54K	Buy	3,514 +2,975	+552%	+$51.7K	﹤0.01%	2206
2021 Q2	$10K	Hold	539	–	–	﹤0.01%	2473
2021 Q1	$10K	Sell	539 -256	-32%	-$4.34K	﹤0.01%	2394
2020 Q4	$12K	Hold	795	–	–	﹤0.01%	2291
2020 Q3	$9K	Hold	795	–	–	﹤0.01%	2294
2020 Q2	$10K	Buy	+795	New	+$10.1K	﹤0.01%	2295
2018 Q1	–	Sell	-3,300	Closed	-$9K	–	2379
2017 Q4	$9K	Buy	+3,300	New	+$8.97K	﹤0.01%	2283

Other funds holding XENE

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Macquarie Group's XENE Position: Q4 2022 in Review

Macquarie Group sold out of Xenon Pharmaceuticals (XENE) in Q4 2022, closing a stake of 132 shares — an estimated $24K sold.

Macquarie Group first reported a position in XENE in Q4 2017 and held it in 11 quarters. The position peaked at $110K in Q4 2021. 159 funds tracked by Wall St. Rank hold XENE as of Q4 2022.

Macquarie Group reported no remaining Xenon Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Macquarie Group sold 132 Xenon Pharmaceuticals shares in Q4 2022, an estimated $24K.
Macquarie Group first reported a position in Xenon Pharmaceuticals in Q4 2017 and held it in 11 quarters.
Macquarie Group's Xenon Pharmaceuticals position peaked at $110K in Q4 2021.
159 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q4 2022.

Based on Macquarie Group's 13F filing for Q4 2022, filed 21 Feb 2023.